MX2021015508A - Carbamatos de piridina y su uso como moduladores del receptor glun2b. - Google Patents
Carbamatos de piridina y su uso como moduladores del receptor glun2b.Info
- Publication number
- MX2021015508A MX2021015508A MX2021015508A MX2021015508A MX2021015508A MX 2021015508 A MX2021015508 A MX 2021015508A MX 2021015508 A MX2021015508 A MX 2021015508A MX 2021015508 A MX2021015508 A MX 2021015508A MX 2021015508 A MX2021015508 A MX 2021015508A
- Authority
- MX
- Mexico
- Prior art keywords
- carbamates
- pyridine
- receptor modulators
- glun2b
- pyridine carbamates
- Prior art date
Links
- ZRVFBMJRSGKWEO-UHFFFAOYSA-N carbamic acid;pyridine Chemical class NC(O)=O.C1=CC=NC=C1 ZRVFBMJRSGKWEO-UHFFFAOYSA-N 0.000 title abstract 4
- 108010054200 NR2B NMDA receptor Proteins 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861634P | 2019-06-14 | 2019-06-14 | |
| PCT/EP2020/066400 WO2020249799A1 (en) | 2019-06-14 | 2020-06-12 | Pyridine carbamates and their use as glun2b receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015508A true MX2021015508A (es) | 2022-01-31 |
Family
ID=71120147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015508A MX2021015508A (es) | 2019-06-14 | 2020-06-12 | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11447503B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3983074A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022538774A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220020916A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114007691A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020293584A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021025132A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3143103A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021015508A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020249799A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
| AU2020290772A1 (en) | 2019-06-14 | 2022-01-06 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
| AU2020291188A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators |
| SG11202112407PA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ.ベー. | 置換ピラゾロ-ピリジンアミド及びglun2b受容体調節因子としてのその使用 |
| EP3983413A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators |
| US20220324860A1 (en) | 2019-06-14 | 2022-10-13 | Janssen Pharmaceutica Nv | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| BR112021025132A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Carbamatos de piridina e seu uso como moduladores do receptor glun2b |
| EP4384165B1 (en) * | 2021-08-09 | 2025-07-09 | Janssen Pharmaceutica NV | Monoacylglycerol lipase modulators for use in autism spectrum disorders |
| LU605402B1 (en) * | 2024-07-11 | 2026-07-14 | Sea4Us Biotecnologia E Recursos Marinhos Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980357A (en) | 1990-03-01 | 1990-12-25 | Pfizer Inc. | Azolidinedione derivatives |
| GB9407447D0 (en) * | 1994-04-14 | 1994-06-08 | Glaxo Group Ltd | Chemical compounds |
| CA2262502C (en) | 1996-07-31 | 2002-11-26 | Nikken Chemicals Co., Ltd. | 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same |
| WO2002000629A1 (en) | 2000-06-26 | 2002-01-03 | Merck & Co., Inc. | Iminopyrimidine nmda nr2b receptor antagonists |
| US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| KR20040111445A (ko) | 2002-03-28 | 2004-12-31 | 에자이 가부시키가이샤 | 신경퇴행성 질환 치료용 c─Jun N─말단 키나아제억제제로서의 7─아자인돌 |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| CN1656079A (zh) | 2002-05-31 | 2005-08-17 | 卫材株式会社 | 吡唑化合物和含有该化合物的药物组合物 |
| AU2005214375A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Triazole compounds and their use as metabotropic glutamate receptor antagonists |
| EP1805142A4 (en) | 2004-09-23 | 2009-06-10 | Reddy Us Therapeutics Inc | PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME |
| US7807704B2 (en) | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| KR20100017372A (ko) | 2007-05-25 | 2010-02-16 | 애보트 게엠베하 운트 콤파니 카게 | 향대사성 글루타메이트 수용체 2(mglu2 수용체)의 포지티브 조절자로서의 헤테로사이클릭 화합물 |
| WO2009004430A1 (en) * | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| WO2009028543A1 (ja) | 2007-08-30 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 置換ピラゾール誘導体 |
| WO2009058261A1 (en) | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | Modulation of sleep with nr2b receptor antagonists |
| US20110053951A1 (en) | 2008-03-27 | 2011-03-03 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
| EP2298731A4 (en) | 2008-06-25 | 2011-09-21 | Takeda Pharmaceutical | AMIDE COMPOUND |
| DK2308877T3 (da) | 2008-08-05 | 2014-04-22 | Daiichi Sankyo Co Ltd | Imidazopyridin-2-on-derivater |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| WO2010043396A1 (en) | 2008-10-16 | 2010-04-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| CN102264743B (zh) | 2008-11-25 | 2015-02-11 | 罗彻斯特大学 | Mlk抑制剂及其使用方法 |
| US8969342B2 (en) | 2009-03-20 | 2015-03-03 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| WO2011022348A1 (en) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid amide hydrolase |
| EP2579717A4 (en) | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 |
| JP5990106B2 (ja) | 2011-01-28 | 2016-09-07 | 佐藤製薬株式会社 | 縮環化合物 |
| JP2012188363A (ja) | 2011-03-09 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | アザベンゾイミダゾロン誘導体 |
| AR086254A1 (es) | 2011-05-26 | 2013-11-27 | Lilly Co Eli | Derivados de imidazol utiles para el tratamiento de artritis |
| PL2570415T3 (pl) | 2011-09-19 | 2016-01-29 | Sanofi Sa | N-[4-(1H-pirazolo[3,4-b]pirazyn-6-ylo)-fenylo]-sulfonamidy i ich zastosowanie jako farmaceutyki |
| WO2013060029A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp | Allosteric modulators of metabotropic glutamate receptors |
| WO2013130855A1 (en) | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| WO2014124651A1 (en) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists |
| TW201444820A (zh) | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶cdk9激酶抑制劑 |
| CN105073747B (zh) | 2013-03-15 | 2017-06-06 | 普莱希科公司 | 杂环化合物及其应用 |
| KR102307566B1 (ko) | 2013-06-21 | 2021-10-05 | 제니쓰 에피제네틱스 리미티드 | 신규한 바이사이클릭 브로모도메인 억제제 |
| JP6612751B2 (ja) | 2013-07-31 | 2019-11-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Btkの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用 |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| PT3180315T (pt) | 2014-08-15 | 2020-05-27 | Janssen Pharmaceuticals Inc | Pirazoles |
| EP3180329B1 (en) | 2014-08-15 | 2020-03-18 | Janssen Pharmaceuticals, Inc. | Triazoles as nr2b receptor inhibitors |
| WO2016081649A1 (en) | 2014-11-18 | 2016-05-26 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto |
| CN107406435A (zh) | 2015-02-23 | 2017-11-28 | 百时美施贵宝公司 | 新的治疗丙型肝炎的化合物 |
| MA41803A (fr) | 2015-03-24 | 2018-01-30 | Almirall Sa | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques |
| MX2018000352A (es) | 2015-07-09 | 2018-08-15 | Janssen Pharmaceutica Nv | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. |
| KR20180108822A (ko) | 2016-02-10 | 2018-10-04 | 얀센 파마슈티카 엔.브이. | Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸 |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
| CN110831593A (zh) | 2017-06-14 | 2020-02-21 | 特维娜有限公司 | 用于调节s1p1活性的化合物及其使用方法 |
| EP3774732A4 (en) | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| CN110294756A (zh) | 2019-06-04 | 2019-10-01 | 广州市原子高科同位素医药有限公司 | GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备 |
| AU2020291188A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators |
| US20220324860A1 (en) | 2019-06-14 | 2022-10-13 | Janssen Pharmaceutica Nv | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| BR112021025132A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Carbamatos de piridina e seu uso como moduladores do receptor glun2b |
| SG11202112407PA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
| AU2020290772A1 (en) | 2019-06-14 | 2022-01-06 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
| EP3983413A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators |
-
2020
- 2020-06-12 BR BR112021025132A patent/BR112021025132A2/pt not_active IP Right Cessation
- 2020-06-12 WO PCT/EP2020/066400 patent/WO2020249799A1/en not_active Ceased
- 2020-06-12 US US16/899,809 patent/US11447503B2/en active Active
- 2020-06-12 JP JP2021573608A patent/JP2022538774A/ja not_active Withdrawn
- 2020-06-12 EP EP20734123.1A patent/EP3983074A1/en not_active Withdrawn
- 2020-06-12 AU AU2020293584A patent/AU2020293584A1/en not_active Abandoned
- 2020-06-12 MX MX2021015508A patent/MX2021015508A/es unknown
- 2020-06-12 KR KR1020227001091A patent/KR20220020916A/ko not_active Withdrawn
- 2020-06-12 CN CN202080043610.3A patent/CN114007691A/zh active Pending
- 2020-06-12 CA CA3143103A patent/CA3143103A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114007691A (zh) | 2022-02-01 |
| AU2020293584A1 (en) | 2022-01-20 |
| JP2022538774A (ja) | 2022-09-06 |
| BR112021025132A2 (pt) | 2022-01-25 |
| WO2020249799A1 (en) | 2020-12-17 |
| CA3143103A1 (en) | 2020-12-17 |
| US11447503B2 (en) | 2022-09-20 |
| KR20220020916A (ko) | 2022-02-21 |
| EP3983074A1 (en) | 2022-04-20 |
| US20200392154A1 (en) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021015511A (es) | Carbamatos de pirazina y sus usos como moduladores del receptor glun2b. | |
| EP4603142A3 (en) | Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof | |
| PH12022550359A1 (en) | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | |
| MX2021015500A (es) | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. | |
| MX2021013197A (es) | Cicloalquilos sustituidos como moduladores de la vía integrada del estrés. | |
| PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| BR112021021754A2 (pt) | Cicloalquilas substituídas como moduladoras da via de estresse integrada | |
| EP4556067A3 (en) | Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof | |
| BR112021025132A2 (pt) | Carbamatos de piridina e seu uso como moduladores do receptor glun2b | |
| NZ757081A (en) | Somatostatin modulators and uses thereof | |
| CR20210615A (es) | Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b | |
| MX2020007731A (es) | Compuestos moduladores de receptor de estrogeno. | |
| NZ737399A (en) | Ccr2 modulators | |
| CR20210580A (es) | Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b | |
| NZ750174A (en) | Somatostatin modulators and uses thereof | |
| MX2020013085A (es) | Antagonistas del receptor de subtipo 2 de melanocortina (mc2r) y usos de los mismos. | |
| PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| MX2020007586A (es) | Proceso de fabricacion de moduladores de somatostatina. | |
| MX2018000352A (es) | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. | |
| MX2024014462A (es) | Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a | |
| WO2019193516A3 (en) | Substituted pyridine and pyrimidines and their use as glun2b receptor modulators | |
| MX2019006877A (es) | Derivados de 4-pregenen-11ss-17-21-triol-3,20-diona para el tratamiento de afecciones oculares. | |
| MX2022011310A (es) | Azabiciclo y derivados de diazepina para tratar trastornos oculares. | |
| MX2020009459A (es) | Moduladores de ror-gamma espirocíclico. | |
| PH12021552839A1 (en) | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |